Monoclonal antibody against B-cell psoriasis leukemia, a target of cancer artificial intelligence
①Nature：Cancer will cost the world $25 trillion over next 30 years
In the next 30 years, cancer may cost the world $25 trillion.
DOI :10.1038/d41586-023-00634-9
②Seminars in Cancer Biology：Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction
Review: Application and development of artificial intelligence in the field of precision oncology: new antigen recognition, antibody design and immunotherapy response prediction.
DOI :10.1016/j.semcancer.2023.02.007
③Molecular Cancer：CD39/CD73/A2AR pathway and cancer immunotherapy
Review: New progress in pathophysiological function of CD39/CD73/A2AR pathway in cancer development, metastasis and drug resistance.
DOI :10.1186/s12943-023-01733-x
④Immunity：B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection
B cell receptor signal transduction in germinal center prolongs the survival of B cells and initiates the selection of B cells.
DOI :10.1016/j.immuni.2023.02.003
⑤Frontiers in Immunology：Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis
The metabolic recombination of miR-31-5p in keratinocytes determines the intervention on psoriasis.
DOI :10.15252/emmm.202215674
⑥Journal of Hematology & Oncology：Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
The latest drug research and new scheme progress of American Society of Hematology (ASH) for acute myeloid leukemia (AML)
DOI :10.1186/s13045-023-01411-x
⑦FDA extended the review of adult Roctavian with severe hemophilia A because of "significant changes in a large number of additional data"
⑧ A small molecule MET inhibitor, gumetinib, which was developed by Shanghai Institute of Pharmacology, China Academy of Sciences, was approved for marketing, and it was used for locally advanced or metastatic non-small cell lung cancer (NSCLC) with the jump mutation (METex14 jump) in exon 14 of mesenchymal-epithelial transforming factor (MET).
⑨ The clinical study of Relma-cel targeting CD19 for first-line high-risk large B-cell lymphoma was officially launched.
⑩ Lilly will terminate the research and development of Solanezumab for Alzheimer’s disease because it fails to slow down the cognitive decline of preclinical Alzheimer’s patients.
The world of scientific exploration is full of challenges. AtaGenix pays tribute to every pioneer and is more committed to becoming your trusted partner!